Insight Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.82M Sell
1,521
-4
-0.3% -$4.09K 0.32% 44
2026
Q1
$1.4M Buy
1,525
+1
+0.1% +$1.01K 0.27% 52
2025
Q4
$1.64M Buy
1,524
+31
+2% +$29.6K 0.25% 67
2025
Q3
$1.14M Buy
1,493
+259
+21% +$193K 0.17% 88
2025
Q2
$961K Buy
1,234
+127
+11% +$98.7K 0.15% 94
2025
Q1
$915K Buy
1,107
+244
+28% +$203K 0.16% 91
2024
Q4
$668K Sell
863
-82
-9% -$67.9K 0.11% 118
2024
Q3
$838K Buy
945
+17
+2% +$15.3K 0.14% 107
2024
Q2
$841K Buy
928
+30
+3% +$24K 0.15% 101
2024
Q1
$699K Buy
898
+134
+18% +$95.4K 0.13% 117
2023
Q4
$445K Buy
764
+15
+2% +$8.76K 0.09% 157
2023
Q3
$402K Hold
749
0.09% 166
2023
Q2
$351K Buy
749
+42
+6% +$17.6K 0.08% 191
2023
Q1
$243K Sell
707
-1,054
-60% -$355K 0.06% 261
2022
Q4
$643K Buy
1,761
+552
+46% +$196K 0.22% 118
2022
Q3
$391K Sell
1,209
-3
-0.2% -$951 0.15% 174
2022
Q2
$371K Buy
1,212
+392
+48% +$118K 0.13% 197
2022
Q1
$235K Buy
+820
New +$211K 0.07% 284

Other funds holding LLY

Insight Advisors's LLY Position: Q2 2026 in Review

Insight Advisors reduced its Eli Lilly (LLY) stake by 0.26% in Q2 2026, selling an estimated $4.09K and leaving 1,521 shares worth $1.82M. The position accounts for 0.32% of the portfolio, ranked #44.

Insight Advisors first reported a position in LLY in Q1 2022 and has held it in 18 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Insight Advisors held 1,521 shares of Eli Lilly worth $1.82M as of Q2 2026.
  • Insight Advisors sold 4 Eli Lilly shares in Q2 2026, an estimated $4.09K.
  • Eli Lilly made up 0.32% of Insight Advisors's portfolio in Q2 2026, its #44 holding.
  • Insight Advisors first reported a position in Eli Lilly in Q1 2022 and has held it in 18 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Insight Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.